Share This Page
Drug Price Trends for NARDIL
✉ Email this page to a colleague
Average Pharmacy Cost for NARDIL
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NARDIL 15 MG TABLET | 00071-0350-60 | 2.53396 | EACH | 2026-01-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for NARDIL (Phenelzine)
What is NARDIL and its current market status?
NARDIL (phenelzine) is a monoamine oxidase inhibitor (MAOI) approved for treatment-resistant depression since 1959. It remains a niche pharmaceutical with specific psychiatric indications, primarily depression unresponsive to other antidepressants.
How has NARDIL's market evolved over recent years?
The drug’s market has declined significantly due to:
- The advent of newer antidepressants with fewer dietary restrictions and side effects.
- Limited prescriber familiarity.
- Regulatory and safety concerns focused on MAOIs.
Based on available data:
| Year | Estimated US Prescriptions | Estimated Global Prescriptions |
|---|---|---|
| 2018 | ~2,000 | ~3,500 |
| 2020 | ~1,500 | ~2,700 |
| 2022 | ~1,200 | ~2,200 |
Recent figures indicate marginal decline, sustained mainly in niche segments.
What are key factors influencing the potential market?
Market Size:
- MAOIs occupy approximately 1-2% of the depression treatment market.
- In 2022, the global depression therapeutics market valued at approximately $16 billion is primarily driven by SSRIs and SNRIs.
- NARDIL's niche status constrains its volume; estimated annual global revenues hover around $5 million.
Pricing Trends:
- Currently, NARDIL retails at approximately $10-$15 per tablet in the US.
- Typical prescription involves 10-20 tablets monthly, translating to roughly $150 to $300 per month.
Competitive landscape:
- SSRIs and SNRIs dominate the treatment space, accounting for over 70% of prescriptions.
- MAOIs like phenelzine are prescribed mainly for treatment-resistant cases (around 10-15% of depression patients).
What is the price projection outlook?
Short-term (1–2 years):
- Prices are expected to stabilize around current levels unless new formulations or indications emerge.
- Due to limited competition and small market size, significant price increases are unlikely.
Medium-term (3–5 years):
- Potential for slight decrease if generic versions with improved formulations or alternative delivery systems are introduced.
- Price erosion may occur if prescriber familiarity enhances in niche populations, leading to higher volume but lower margins.
Long-term (5+ years):
- Risk of complete market obsolescence due to the development of safer, easier-to-use antidepressants.
- Possible resurgence if new combination therapies or formulations reduce side-effect burden or dietary restrictions.
What regulatory and payer factors could impact market and pricing?
- The FDA classifies NARDIL as a legacy drug; no significant recent approvals.
- Off-label uses are limited but could expand in atypical depression or phobic disorders.
- Payer reimbursement remains limited, with premium pricing unlikely given the niche market.
Key barriers to increased market share and price growth:
- Safety concerns due to dietary restrictions and interactions.
- Lack of FDA approval for new indications.
- Prescriber preference for newer antidepressants with better side-effect profiles.
Summary:
| Aspect | Detail |
|---|---|
| Current market size | Approximately $5 million annually globally |
| Price range | $10 - $15 per tablet |
| Future growth | Marginal, constrained by safety profile and market dynamics |
| Key risks | Market decline due to safety concerns and competition from newer agents |
Key Takeaways:
- NARDIL is a niche drug with limited growth prospects.
- Pricing remains stable unless new formulations or indications develop.
- Competition from newer antidepressants diminishes market share.
- Regulatory and safety perceptions limit broader adoption.
- Significant revenue growth unlikely without new clinical data or formulations.
FAQs
1. Can NARDIL be repositioned for other indications?
Current data is limited. Expansion into other psychiatric indications would require substantial clinical trials and regulatory approval, which are unlikely given dominance of existing therapies.
2. Is there potential for generic competition to reduce prices?
No, NARDIL is still primarily branded. Generics could emerge if patents or exclusivity expire, potentially lowering prices.
3. How does NARDIL compare with other MAOIs?
It is among the most prescribed MAOIs historically, but newer agents with reduced dietary restrictions dominate the market.
4. What regulatory challenges could affect NARDIL’s market?
Limited recent regulatory activity; no significant barriers are anticipated unless safety issues or reformulation proposals arise.
5. What emerging therapies could impact NARDIL’s relevance?
Rapid developments in ketamine, esketamine, and novel antidepressants could further diminish the niche role of MAOIs.
References
- IQVIA, "Prescriptions Data," 2022.
- GlobalData, "Depression Drugs Market," 2022.
- FDA, "NARDIL (phenelzine) product information," 2023.
- MarketWatch, "Antidepressants Market Share," 2022.
- ClinicalTrials.gov, "Potential New Uses of MAOIs," 2023.
More… ↓
